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Surface enhanced laser desorption/ionisation-time of flight (SELDI-TOF) mass 
spectrometry (MS) is an array based proteomic technology. It combines avariety of 
chromatographic surfaces that bind proteins from biological mixtures according to 
physicochemical properties with MS analysis. The relative expression of proteins 
at specific molecular weights can then be compared among different samples. 
The aim of this work is to establish protein profiles in Cystic Fibrosis (CF) serum 
and airway cell lysate for biomarker identification. These proteins may serve as 
diagnostic/prognostic markers or even as new targets for CF therapy. 
Serum and nasal epithelial cells (collected by brushing) were obtained from 
CF patients (n 13/15) and controls (n 11/9). Protein extracts were applied to a 
range ProteinChip surfaces (anionic exchange, cationic exchange and metal affinity) 
and analysed by SELDI-TOF-MS. The mass spectral data demonstrate a larger 
group of proteins with differential expression in serum compared to nasal cells 
lysate. 45 peaks (p < 0.05) differentiated CF serum from control. 9 peaks (p < 0.05) 
differentiated CF nasal cell lysate from control. 
Further work is required to validate these results in a larger cohort of CF patients 
and to identify candidate biomarkers with MS protein characterisation. 
Work supported by FCT/FEDER research grants (POCTI/SAU-MMO/56163/2004). 
PA is a recipient of FCT doctoral fellowship. CB and DP collaborated equally to 
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2. CFTR Cell biology~Physiology 
1~ Basal control of CFTR gene expression by bicarbonate-sensitive 
soluble adenylyl cyclase in Calu-3 cells 
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Cystic fibrosis is dominated by inflammation and the best-known modulators of 
CFTR gene expression are cytokines and transduction cytosolic pathways stimulated 
by inflammation. However, one may hypothesize that the expression of the CFTR 
gene, which encodes awell-defined anion channel, should also be controlled by C1 
or HCO 3 concentrations. The effect of increasing extracellular HCO 3 concentration 
was tested on the Calu-3 cell contents in CFTR mRNA and protein by Northern- 
and Western-blotting. Varying the HCO 3 concentration f the basal culture medium 
between 0 and 50 retool/1 dose-dependently increased the CFTR expression, with an 
optimal effect observed with 25 retool/l, and this resulted from enhanced CFTR gene 
transcription. No variation was observed on the expression of the cyclooygenase-2 
gene, chosen as an example of an inflammation-responsive gene, and the increase 
in CFTR mRNA cell content induced by the inflammatory cytokine IL-I~ was 
not significantly modified by the extracellular bicarbonate concentration. The 
bicarbonate supplementation concomitantly induced a cAMP production inhibited 
by 2-OH E2, the selective inhibitor of the soluble adenylyl cyclase, and intranuclear 
phosphorylation f the transcription factor CREB. Inhibition of this transduction 
pathway with either 2-OH E2 or the PKA inhibitor H-89 suppressed the bicarbonate- 
induced stimulation of basal CFTR gene expression. 
Altogether, these results show that the CFTR gene expression is submitted to a 
double system of regulation corresponding to the double function of the protein 
involved in ion transport and response to inflammatory stimuli. 
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Introduction: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and 
multidrug resistance (MDRlb) proteins are members of the "ATP-binding cassette" 
superfamily of transporters. Up-regulation ofMDR has previously been shown after 
macrolide treatment in animals [1,2]. A study was performed to see whether the 
same was true for patients with Cystic Fibrosis (CF). 
Material and methods: 6 adult CF patients received AZM (500mg daily) for 
6 months. FVC%, FEV 1% and number of acute exacerbations were compared 
before and after treatment. Nasal biopsies were taken from the patients before 
and after AZM treatment and from age-and sex matched healthy controls. 14 gm 
cryosections were hybridized with oligonucleotide probes complementary to mR- 
NAs sequences encoding MDRlb-1, MDRlb-2, MDRlb-3, CFTR-1, CFTR-2 and 
CFTR-3 as described previously [3]. 
Results: Significant improvement i  FEV 1% and fewer exacerbations were observed 
among the patients, mRNA expression of MDR and CFTR was detected in all 
biopsies with no significant difference noticed after treatment. 
Discussion: As shown by others, the amelioration of the CF patients' status after 
AZM treatment was not linked to MDR or CFTR up-regulation [4]. The anti- 
inflammatory effects previously described for AZM could be an explanation for the 
improvement seen among the patients [5]. 
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Curcumin rescues deltaF508-CFTR via the keratin 18 network 
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The most common mutation in the CFTR gene, AF508, causes retention of 
AF508-CFTR in the endoplasmic reticulum and leads to the absence of CFTR 
C1 channels in the plasma membrane. AF508-CFTR retains some C1 channel 
activity so increased expression of AF508-CFTR in the plasma membrane can 
restore C1 secretion deficiency. Recently, curcumin was shown to rescue AF508- 
CFTR localization and function. In our previous work, the keratin 18 network 
was implicated in AF508-CFTR trafficking. Here, we hypothesized that curcumin 
could restore a functional AF508-CFTR to the plasma membrane acting via the 
K18 network. First, we analyzed the effects of curcumin on the localization 
of AF508-CFTR in different cell lines (HeLa cells stably transfected with WT- 
CFTR or AF508-CFTR, CALU-3 or CFPAC-1 cells) and found it was significantly 
delocalized towards the plasma membrane in AF508-CFTR-expressing cells. We 
also performed a functional assay for the CFTR chloride channel in CFPAC-1 
cells treated or not with curcumin and detected an increase in a cAMP-dependent 
chloride fflux in treated AF508-CFTR-expressing cells. Then, the K18 network was 
analyzed by immunocytochemistry and immunoblot exclusively in curcumin-treated 
or untreated CFPAC-1 cells because of their endogenic AF508-CFTR expression. 
After curcumin treatment, we observed a remodeling of the K18 network and a 
significant increase in K18 Ser52 phosphorylation, a signature of the reorganization 
of intermediate filaments. The last results will be presented. 
